Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 6/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | GRM8 | O00222 | 2/20 | 0.33 |
| ▸ | GRM6 | O15303 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.33 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3464980 | 1.00 | HRH3 (0.38) | HRH3GRM4CYP2C19CYP1A2ALDH1A1 | |
| SCHEMBL3464994 | 1.00 | HRH3 (0.38) | HRH3GRM4CYP2C19CYP1A2ALDH1A1 | |
| SCHEMBL18983664 | 0.86 | GRM4 (0.31) | GRM4CYP2C19CYP1A2ALDH1A1TDP1 | |
| SCHEMBL20985243 | 0.85 | — | — | |
| SCHEMBL301224 | 0.85 | — | — | |
| SCHEMBL20985252 | 0.85 | — | — | |
| SCHEMBL30425354 | 0.82 | ALDH1A1 (0.37) | HRH3GRM4CYP2C19CYP1A2ALDH1A1 | |
| SCHEMBL1634054 | 0.80 | LMNA (0.39) | HRH3GRM4CYP2C19CYP1A2ALDH1A1 | |
| SCHEMBL301094 | 0.80 | — | — | |
| SCHEMBL3464255 | 0.79 | HRH3 (0.37) | HRH3KMT2AKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071651-B2 | 5-amino-4-hydroxy-7-(imidazo [1,2-A] pyridin-6-ylmethyl)-8-methyl-nonamide derivatives and related compounds as renin inhibitors for the treatment of hypertension | NOVARTIS AG (CH) | 2011-12-06 | — | — | US | disclosed |
| US-20100063087-A1 | 5-Amino-4-Hydroxy-7-(Imidazo [1,2-A] Pyridin-6-Ylmethyl)-8-Methyl-Nonamide Derivatives and Related Compounds as Renin Inhibitors for the Treatment of Hypertension | SPEEDEL EXPERIMENTA AG (CH) | 2010-03-11 | — | — | US | disclosed |
| EP-1948654-B1 | 5-AMINO-4-HYDROXY-7- (IMIDAZO [1,2-A] PYRIDIN-6- YLMETHYL)-8-METHYL-NONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2009-06-24 | — | — | EP | disclosed |
| EP-1958666-A1 | Heterocyclic-substituted alkanamides as therapeutic compounds | Speedel Experimenta AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| EP-1948654-A1 | 5-AMINO-4-HYDROXY-7- (IMIDAZO [1,2-A] PYRIDIN-6- YLMETHYL)-8-METHYL-NONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | Speedel Experimenta AG (CH) | 2008-07-30 | — | — | EP | disclosed |
| US-20080176947-A1 | Heterocyclic-Substituted Alkanamides Useful as Renin Inhibitors | NOVARTIS AG (CH) | 2008-07-24 | — | — | US | disclosed |
| EP-1856032-A1 | HETEROCYCLIC-SUBSTITUTED ALKANAMIDES USEFUL AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2007-11-21 | — | — | EP | disclosed |
| WO-2007031558-A1 | 5-AMINO-4-HYDROXY-7- (IMIDAZO [1,2-A] PYRIDIN-6- YLMETHYL)-8-METHYL-NONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | SPEEDEL EXPERIMENTA AG (CH) | 2007-03-22 | — | — | WO | disclosed |
| WO-2006095020-A1 | HETEROCYCLIC-SUBSTITUTED ALKANAMIDES USEFUL AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176947-A1 | Heterocyclic-Substituted Alkanamides Useful as Renin Inhibitors | REN, ACE, AGTR1 | HRH3 191/4885GRM4 3637/4885CYP2C19 186/4885 |
| US-20100063087-A1 | 5-Amino-4-Hydroxy-7-(Imidazo [1,2-A] Pyridin-6-Ylmethyl)-8-Methyl-Nonamide Derivatives and Related Compounds as Renin Inhibitors for the Treatment of Hypertension | REN, AGTR1, AGTR2 | HRH3 460/4885GRM4 2981/4885CYP2C19 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.